Form 4: Gossamer Bio EVP Waage's Options Repriced to $0.45

Sentiment:

Insider Transaction Report 20 March 2026 4:14 PM

Gossamer Bio, Inc. repriced certain outstanding stock options for EVP Christian Waage to an exercise price of $0.45 per share, effective March 19, 2026.

Worse than expectedThe repricing of options indicates that the company's stock price has likely fallen significantly below the original exercise prices, rendering the options underwater and ineffective as an incentive.This action effectively grants new options at a lower price, which can be dilutive to existing shareholders and may be perceived as rewarding management for underperformance.

Summary

Christian Waage, EVP, Tech Ops and Admin at Gossamer Bio, Inc. (GOSS), had certain outstanding stock options repriced.
The repricing, effective March 19, 2026, reduced the exercise price of these options to $0.45 per share.
The original exercise prices for these options ranged from $0.838 to $2.88 per share.
A total of 1,990,084 stock options were affected by this one-time repricing.
All other terms and conditions of the repriced options, including vesting schedules and terms, remain unchanged.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal for shareholders, as it suggests past stock underperformance and can be dilutive, despite potentially re-incentivizing a key executive.

Positives

The repricing of stock options to a lower exercise price of $0.45 significantly increases the in-the-money value for Christian Waage, aligning his incentives with potential future stock price appreciation from a lower base.
This action could serve as a retention mechanism for a key executive by restoring the motivational value of previously underwater options.

Negatives

Option repricing can be viewed negatively by shareholders as it effectively grants new options at a lower price, potentially diluting existing shareholder value, especially if the original options were underwater due to poor company performance.
It may signal that the company's stock price has performed poorly, leading to options being out-of-the-money.

Risks

Shareholder dissatisfaction and potential governance concerns regarding executive compensation practices, particularly if the repricing is perceived as rewarding management for underperformance.
Potential for increased share dilution if the repriced options are exercised, impacting earnings per share.

Future Outlook

Industry Context

StockSavvy.ai notes that option repricing is a practice often employed by companies, particularly in sectors like biotechnology where stock volatility can be high, to re-incentivize executives when options become significantly underwater. While it can boost executive morale and retention, it often draws scrutiny from governance advocates and shareholders who may view it as a transfer of value from shareholders to management without a corresponding increase in performance.

Comparison to Industry Standards

Option repricing is a controversial practice. While not uncommon, particularly in industries with volatile stock performance, it often deviates from best-in-class corporate governance standards that prioritize shareholder value and avoid retrospective adjustments to compensation.
Companies like Apple or Microsoft, known for strong governance, typically avoid repricing options, instead relying on new grants or performance-based awards.
In the biotech sector, where stock prices can be highly sensitive to clinical trial results, repricing has been observed in companies facing significant stock declines, such as Athersys (ATHX) in 2022 or Sorrento Therapeutics (SRNE) in previous years, to retain key talent. However, such actions are often met with investor skepticism regarding management accountability.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Executive Compensation Policy	One-time repricing of certain outstanding stock options under the 2019 Incentive Award Plan, reducing the exercise price to $0.45 per share.	03/19/2026	This action impacts executive compensation structure by re-incentivizing the EVP, but may raise questions about shareholder value and dilution.

Stakeholder Impact

Shareholders: Potential negative impact due to perceived dilution and concerns over executive compensation practices, especially if the repricing is seen as rewarding underperformance.
Employees (specifically Christian Waage): Positive impact through restored incentive value of stock options, potentially increasing motivation and retention.

Key Dates

Date	Description
03/19/2026	Effective date of the one-time repricing of certain outstanding stock options.
03/20/2026	Date the Form 4 was signed by Attorney-in-Fact Jeff Boerneke.
03/25/2029	Expiration date for 70,000 stock options with a new exercise price of $0.45.
02/14/2030	Expiration date for 47,667 stock options with a new exercise price of $0.45.
02/25/2031	Expiration date for 60,000 stock options with a new exercise price of $0.45.
01/05/2032	Expiration date for 126,667 stock options with a new exercise price of $0.45.
12/06/2032	Expiration date for 157,500 stock options with a new exercise price of $0.45.
03/19/2033	Expiration date for 157,500 stock options with a new exercise price of $0.45.
11/19/2033	Expiration date for 125,000 stock options with a new exercise price of $0.45.
01/01/2034	Expiration date for 375,000 stock options with a new exercise price of $0.45.
03/03/2035	Expiration date for 440,000 stock options with a new exercise price of $0.45.
01/01/2036	Expiration date for 506,250 stock options with a new exercise price of $0.45.

Recommendation

hold

The option repricing for a key executive indicates past stock underperformance, which is a negative signal for investors. However, it also aims to re-incentivize management. Without broader financial or operational updates, a 'hold' recommendation is appropriate to assess if this action is part of a larger turnaround strategy or merely a governance concern.

Keywords

Gossamer Bio, GOSS, Stock Options, Option Repricing, Executive Compensation, Form 4, Insider Transaction, Christian Waage, Equity Incentive Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.